Auto-generated from public data. Not the firm's stated position.
BaseLaunch appears to focus on early-stage biotech investments, particularly in oncology and immunotherapy therapeutics, with a typical check size up to €0.5M at the pre-seed and seed stages. Recent portfolio companies suggest concentration in targeted cancer therapeutics and immune-modulating approaches, indicating a thesis around novel mechanisms in oncology.
Generated 1 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Up to €500k
Browse similar check sizes →Website reachable as of Oct 2026. Focus and check size as listed by the firm, not independently verified.
Learn what BaseLaunch and similar investors look for:
Biotech pitch guideTips, programs, and cultural notes
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.